N.1 Labs receives approval to initiate prospective advanced gastric cancer study
N.1 Labs has received approval to conduct a prospective expanded access interventional study pertaining to CURATE.AI-driven optimisation of gastric cancer combination therapy (metastatic/advanced). This is a N-of-1 clinical trial and is not currently recruiting additional patients (In collaboration with Tan Tock Seng Hospital).
N.1 Labs publishes Cover Article on MCRPC patient
N.1 Labs (National University of Singapore) utilises its CURATE.AI platform in clinical study, reporting durable response and halted disease progression in MCRPC patient in collaboration with Zenith Epigenetics and UCLA. Prof. Dean Ho serves as senior corresponding author of Cover Article in Advanced Therapeutics.
The article can be found at: https://onlinelibrary.wiley.com/toc/23663987/2018/1/6
Links to major news articles are provided below:
N.1 Labs publishes article with collaborators in Science Translational Medicine
The Quadratic Phenotypic Optimization Platform (QPOP) was used to agnostically develop novel combination therapies for multiple myeloma using artificial intelligence.
The article can be found at: http://stm.sciencemag.org/content/10/453/eaan0941
N.1 Labs PI Dean Ho elected Vice Chair, Gordon Conference on Personalized Medicine
7.29.18 (Hong Kong)
Prof. Dean Ho to become Co-Vice Chair, GRC on Personalized Medicine in 2020 and Co-Chair, GRC on Personalized Medicine in 2022.
CURATE.AI platform is featured in Nature Medicine article
11.07.17 (Los Angeles, CA)
Our CURATE.AI platform was featured in a Nature Medicine news article, which can be found at: https://www.nature.com/articles/nm1117-1244
N.1 Labs Team Members Publish Most Comprehensive Study of Nanodiamond Safety to Date in ACS Nano, a Leading Journal in the Fields of Nanotechnology and Nanoscience.
7.20.16 (Los Angeles, CA)
Dr. Laura Moore, Dr. Eiji Osawa, Dr. Edward Chow, and Dr. Dean Ho have spearheaded an effort to conduct histological, hematological, and urine analysis of nanodiamond safety in multiple models. This comprehensive assessment of nanodiamond biocompatibility served as the foundation for the recently listed study that is validating a nanodiamond-fortified biomaterial. This trial can be found at www.clinicaltrials.gov under registry number NCT02698163. A link to the paper and abstract can be found at:
N.1 Labs Team Members and Collaborators Give Invited Lectures at the First Ever Gordon Research Conference on Personalized Medicine.
7.15.16 (Hong Kong)
Dr. Dean Ho, Dr. Ali Zarrinpar, and Dr. Edward Chow recently gave invited lectures at the inaugural Gordon Research Conference on Personalized Medicine, held at the Institute for Advanced Studies at the Hong Kong University of Science and Technology. Attended by leading global visionaries from academia, industry, and regulatory agencies in the burgeoning fields of personalized and precision medicine, this conference forged a pathway to realize powerful new treatment modalities for clinical translation. Of note, Drs. Ho, Zarrinpar, and Chow are collaborating together as Principal Investigators/Co-Principal Investigators on multiple IRB approved clinical studies.
N.1 Labs Principal Investigator Serves on XPRIZE Panel
3.08.16 (Los Angeles, CA)
Dr. Dean Ho, Principal Investigator of N:1 Labs, was recently featured on a panel of visionaries and thought leaders at the XPRIZE Future of Medicine panel. The panel was moderated by Dr. Peter Diamandis, Executive Chairman of the XPRIZE Foundation. More information can be found at: http://futurizex.ucla.edu/speaker-series/